1. Home
  2. LIFE

LIFE

aTyr Pharma Inc.

Logo aTyr Pharma Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-22-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Founded: 2005 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 108.7M IPO Year: 2015
Target Price: $23.67 AVG Volume (30 days): 553.8K
Analyst Decision: Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.94 EPS Growth: N/A
52 Week Low/High: $1.08 - $2.70 Next Earning Date: 05-07-2024
Revenue: $353,000 Revenue Growth: -96.60%
Revenue Growth (this year): 524.08% Revenue Growth (next year): 328.60%

Share on Social Networks:

Stock Insider Trading Activity of aTyr Pharma Inc. (LIFE)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Broadfoot Jill Marie LIFE Chief Financial Officer Feb 5 '24 Sell $1.69 1,590 $2,687.10 20,821 SEC Form 4